BridgeBio Pharma: Discovering and Developing Drugs for Patients With Genetic Diseases*



Thousands of rare and genetic diseases, such as Tay-Sachs, sickle cell anemia, and various cancers, affect more than 350 million people globally. Many of these diseases are considered rare, and most of them are acute with intense symptoms that compromise quality of life and result in high mortality rates. Unfortunately, nearly 30 percent of individuals with genetic diseases are not expected to live past the age of five.

Portfolio of drugs and interventions targeting

12+

genetic diseases

BridgeBio is working to change that by creating effective, targeted treatments for patients with genetic diseases. Through its differentiated biopharmaceutical discovery and development platform, BridgeBio has developed a portfolio of therapeutics that are targeting more than a dozen genetic diseases for which BridgeBio has specific expertise. Across the spectrum from pre-clinical to late-stage clinical development, innovation and empathy remain critical to the BridgeBio ethos. The more than 50 employees at BridgeBio who are dedicated to research and development seek to develop therapies that target genetic mutations and stop the diseases at their source. In the coming years, BridgeBio hopes to use its differentiated platform to launch therapies that contribute meaningful solutions to patients with genetic diseases.

* The case study about the company from the health care growth portfolio shown above represents what we believe to be the most demonstrative example of the corresponding challenge. The specific portfolio company identified is not representative of all of the investments made, sold, or recommended for advisory clients, and it should not be assumed that the investment in the company identified was or will be profitable. Sourced information for this case study is Global Genes: Rare Diseases Facts and Statistics (2015).